EFM
NBIX icon

E Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

E Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Sell
2,572
-1,917
-43% -$284K 0.01% 312
2026
Q1 		$591K Buy
+4,489
New +$596K 0.02% 252
2025
Q2 		$1.09M Sell
8,642
-620
-7% -$71.1K 0.05% 160
2025
Q1 		$1.02M Buy
9,262
+1,821
+24% +$231K 0.05% 166
2024
Q4 		$1.02M Sell
7,441
-1,446
-16% -$179K 0.05% 145
2024
Q3 		$1.02M Buy
8,887
+1,568
+21% +$215K 0.05% 144
2024
Q2 		$1.01M Buy
7,319
+4,206
+135% +$577K 0.06% 127
2024
Q1 		$429K Sell
3,113
-983
-24% -$134K 0.03% 188
2023
Q4 		$540K Sell
4,096
-89
-2% -$10.2K 0.03% 147
2023
Q3 		$471K Sell
4,185
-598
-13% -$63K 0.04% 129
2023
Q2 		$451K Buy
4,783
+752
+19% +$73.5K 0.04% 130
2023
Q1 		$408K Buy
4,031
+425
+12% +$44.2K 0.03% 161
2022
Q4 		$431K Sell
3,606
-867
-19% -$102K 0.04% 165
2022
Q3 		$475K Sell
4,473
-170
-4% -$17.2K 0.04% 134
2022
Q2 		$453K Buy
4,643
+1,638
+55% +$151K 0.04% 163
2022
Q1 		$282K Buy
+3,005
New +$255K 0.01% 220

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

E Fund Management's NBIX Position: Q2 2026 in Review

E Fund Management reduced its Neurocrine Biosciences (NBIX) stake by 43% in Q2 2026, selling an estimated $284K and leaving 2,572 shares worth $433K. The position accounts for 0.01% of the portfolio, ranked #312.

E Fund Management first reported a position in NBIX in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.09M in Q2 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • E Fund Management held 2,572 shares of Neurocrine Biosciences worth $433K as of Q2 2026.
  • E Fund Management sold 1,917 Neurocrine Biosciences shares in Q2 2026, an estimated $284K.
  • Neurocrine Biosciences made up 0.01% of E Fund Management's portfolio in Q2 2026, its #312 holding.
  • E Fund Management first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Neurocrine Biosciences position peaked at $1.09M in Q2 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.